You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

List of Excipients in Branded Drug METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

Excipient Strategy and Commercial Opportunities for Metoprolol Tartrate and Hydrochlorothiazide

Last updated: March 1, 2026

What Are the Key Excipient Considerations for Combination Formulations?

Metoprolol tartrate and hydrochlorothiazide (HCTZ) are co-formulated for antihypertensive therapy. The formulation requires careful excipient selection to ensure stability, bioavailability, and patient compliance.

Excipient selection factors:

  • Stability: Both drugs are sensitive to moisture and degradation.
  • Compatibility: Excipients must not react with active pharmaceutical ingredients (APIs).
  • Bioavailability: Excipients like disintegrants or dissolution aids influence absorption.
  • Patient acceptability: Flavoring agents and binders improve compliance.

Common excipients used:

  • Binders: Microcrystalline cellulose, pregelatinized starch
  • Disintegrants: croscarmellose sodium, sodium starch glycolate
  • Lubricants: magnesium stearate, stearic acid
  • Fillers: lactose monohydrate, microcrystalline cellulose
  • Coating agents: hydroxypropyl methylcellulose for controlled release

Manufacturers optimize excipients to minimize pill size, control drug release, and prevent degradation over shelf life.

How Does Excipient Choice Affect Manufacturing and Quality?

  • Processability: Choice of disintegrants influences compression; sensitive APIs may require specific binders.
  • Shelf stability: Hydrophilic excipients like lactose can increase moisture uptake.
  • Regulatory compliance: Excipients must meet pharmacopeial standards; excipient Quality-by-Design (QbD) approaches enhance consistency.
  • Cost: Excipients like microcrystalline cellulose are cost-effective; advanced coating or controlled-release excipients add expense.

What Are the Commercial Opportunities in Excipient Innovation?

Innovation avenues:

  • Modified-release formulations: Use of hydrophilic matrix polymers or osmotic systems increases patent life and market share.
  • Taste-masking excipients: Critical for patient adherence, especially in pediatric or elderly populations.
  • Low-sensitivity excipients: Reduce shelf life issues associated with moisture and heat.
  • Excipient-as-active: Incorporation of bioactive or functional excipients (e.g., antioxidants) can differentiate products.

Current market landscape:

  • The global pharmaceutical excipients market is projected to reach $9.6 billion by 2025, growing at a CAGR of 6%.
  • The demand for high-purity, functional excipients increases, driven by biosimilar and generic formulations.

Patent considerations:

  • Dual drug formulations face patent challenges; excipient innovation offers opportunities to develop new, patentable formulations.
  • Companies patent excipient combinations and formulation techniques rather than APIs.

How Do Regulatory Trends Influence Excipient Strategies?

Regulatory agencies emphasize:

  • Transparency regarding excipient sources and manufacturing.
  • Safety evaluation of excipients in specific populations.
  • Compliance with international standards like ICH Q3A/B, USP, and EP.

Developing excipients with established safety profiles accelerates approval for new formulations.

What Are the Future Trends and Market Drivers?

  • Growing emphasis on controlled and targeted release mechanisms.
  • Demand for excipients that improve solubility and bioavailability.
  • Rising focus on patient-centric formulations, such as lower pill burdens.
  • Increasing prevalence of hypertension worldwide sustains demand.

Summary of Commercial Opportunities

Area Opportunity Description
Patent Extensions Novel excipient combinations Develop unique matrices for extended-release tablets
Formulation Differentiation Taste-masked formulations Improve pediatric adherence
Cost Optimization Bulk manufacturing of standard excipients Reduce production costs
Regulatory Advantage Use of GRAS (Generally Recognized As Safe) excipients Accelerate approval process

Key Takeaways

  • Excipient strategies for metoprolol tartrate/HCTZ influence stability, bioavailability, and patient compliance.
  • Innovation in controlled-release and taste-masking excipients presents significant market potential.
  • Manufacturing efficiencies and regulatory compliance are critical to maintaining market share.
  • Patent protection is increasingly linked to formulation and excipient patents, not APIs.
  • The global excipients market provides expanding opportunities for novel, high-quality ingredients.

FAQs

  1. What are the main excipients used in metoprolol and hydrochlorothiazide tablets?
    Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, lactose monohydrate, and hydroxypropyl methylcellulose.

  2. How does excipient choice affect drug stability?
    Certain excipients can absorb moisture or react with APIs, impacting shelf life and efficacy.

  3. Are there patented excipient formulations for these drugs?
    Yes, patentable innovations include controlled-release matrices and taste-masking techniques.

  4. What regulatory challenges exist for excipient selection?
    Ensuring excipients meet safety standards, source transparency, and regulatory compliance can complicate approval.

  5. What future trends will influence excipient development for antihypertensives?
    Emphasis on controlled release, patient adherence, and bioavailability enhancement drives innovation.


References

[1] Smith, J. (2021). Pharmaceutical Excipients Market Analysis. Journal of Pharmaceutical Sciences, 110(5), 2360-2370.

[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Q3A(R2) Impurities in New Drug Substances. FDA.gov.

[3] International Council for Harmonisation (ICH). (2009). Q3A/B: Impurities in Pharmaceuticals. ICH.org.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.